ANTI-HYPERTENSIVE EFFECT OF RENAL ARTERIES RADIOFREQUENCY DENERVATION IN PATIENTS WITH RESISTANT ARTERIAL HYPERTENSION

Abstract

Objective. To assess the effect of some characteristics of chronic obstructive pulmonary disease (COPD) in patients after elective percutaneous coronary intervention (PCI) on repeat myocardial revascularization frequency in long-term period (up to 3 year). Materials and methods. 135 patients with COPD, who suffered stable ischemic heart disease and were underwent PCI, were included in prospective observational study. Follow-up duration was up to 3 year. Evaluation included comparing the frequency of elective repeat revascularization in regards to frequent COPD exacerbations, COPD severity, lung function and C-reactive protein (CRP) plasm level. Comparing Kaplan-Mayer curves and Cox regression analysis were also applied. Results. Elective repeat myocardial revascularization frequency was 23% and 2,1 times higher among the patients who had frequent COPD exacerbations history (95% CI 1,1-3,9). The difference between Kaplan-Mayers curves was also detected as statistically significant (p=0,016). None of the pulmonary function characteristics had relations with elective repeat revascularization frequency increase. Frequent COPD exacerbations history and CRP plasma level were included in Cox regression model as non-cardiovascular variables (p=0,05 and 0,08 respectively). Conclusions. Frequent COPD exacerbations history and increased CRP plasma level are independent non-cardiovascular variables related to increased risk of elective repeat myocardial revascularization. None of the pulmonary function characteristics had relations with elective repeat revascularization frequency increase.

Keywords

chronic obstructive pulmonary disease / elective percutaneous coronary intervention / repeat myocardial revascularization

References

[1] Российское медицинское общество по артериальной гипертонии - Всероссийское научное общество кардиологов. Диагностика и лечение артериальной гипертензии. Российские рекомендации. Кардиологический вестник, 2015, №1, С.3-31.

[2] Шальнова С.А., Деев А.Д., Оганов Р.Г. Факторы, влияющие на смертность от сердечно- сосудистых заболеваний в российской популяции // Кардиоваск. тер. и профилакт. 2005. Т. 4. №1. С. 4-9.

[3] Всемирная организация здравоохранения. Информационный бюллетень, №317. Январь 2015 г.

[4] Бойцов С. А. , Баланова Ю. А. , Шальнова С. А. и др. Артериальная гипертония среди лиц 25-64 лет: распространенность, осведомленность, лечение и контроль. По материалам исследования ЭССЕ. Кардиоваскулярная терапия и профилактика. 2014; 13 (4): 4-14.

[5] The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high risk hypertensive patients randomized to angiotensin converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) // J. Am. Med. Assoc. 2002. Vol. 288, № 23. P. 2981-2997.

[6] Julius S., Kjeldsen S.E., Brunner H. et al., for the VALUE Trial. VALUE trial: long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. Am. J. Hypertens. 2003. Vol. 16, № 7. P. 544-548.

[7] Lewington S., Clarke R., Qizilbash N. et al. Agespecific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360(9349):1903-1913.

[8] Daugherty S.L. Incidence and prognosis of resistant hypertension in hypertensive patients / S.L. Daugherty, J.D. Powers, D.J. Magid // Circulation. 2012. № 125 (13). P. 1635-1642.

[9] Schmieder RE, Redon J, Grassi G, Resistant Hypertension: Diagnosis, Evaluation, and Treatment: A Scientific Statement From the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research/A.C. David, J. Daniel, T. Stephen // Hypertension. 2008, Apr. P. 1403-1419.

[10] Gupta Ajay K., Nasothimiou, Efthimia G., Chang Baseline predictors of resistant hypertension in the Anglo(Scandinavian Cardiac Outcome Trial (ASCOT): a risk score to identify those at high(risk. Journal of Hypertension 2011; 29 (10): 2004-2013.

[11] Шляхто Е.В., Конради А.О., Цырлин В.А. Вегетативная нервная система и артериальная гипертензия. Санкт-Петербург, 2008, 309 с.

[12] Свешников А.В., Воробьев А.С. Резистентная артериальная гипертония: новые возможности интервенционного лечения. Вестник национального медико-хирургического Центра им. Н.И. Пирогова 2013, т. 8, №1, стр. 109-115.

[13] Григин В.А., Данилов Н.М., Матчин Ю.Г., Чазова И.Е. Радиочастотная денервация почечных артерий. Миф или реальность? Системные гипертензии. 2015; 12 (3): 39-44.

[14] Simplicity HTN-1 Investigators 2011. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension. 2011;57:911-7.

[15] Simplicity HTN-2 Investigators, Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RF, et al. Renal sympathetic denervation in patients with treatment resistant hypertension (The Simplicity THN-2 trial): a randomised control trial. Lancet. 2010. 376:1903-9

[16] Schmieder RE, Redon J, Grassi G, Kjeldsen SE, Mancia G, Narkiewicz K, et al. ESH position paper: renal denervation: an interventionaltherapy of resistant hypertension. J Hypertens, 2012; 30:837-841.

[17] Mahfoud F, Lüscher TF, Andersson B, et al. Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. Euro Heart J 2013; online publish-ahead-of-print 24 April 2013. http://dx.doi.org/10.1093/eurheartj/ eht154

[18] Сулимов В.А., Родионов А.В., Светанкова А.А., Денека И.Э. Ренальная денервация при резистентной артериальной гипертензии. Рациональная фармакотерапия в кардиологии. 2013;9(3):274-279. doi:10.20996/1819-6446-2015-11-3-304-308

[19] Рипп Т.М., Мордовин В.Ф., Пекарский С.Е. и др. Симпатическая денервация почечных артерий для лечения резистентной гипертензии, ультразвуковой контроль безопасности метода. Артериальная гипертония, 2013,Том 19, № 2 , С.43-51

[20] Kjeldsen S, Mancia G, Narkiewicz K, et al. ESH Position Paper: renal denervation - an interventional therapy of resistant hypertension. J Hypertens. 2012. 30(5):837-41.

RIGHTS & PERMISSIONS

Gapon L.I., Mikova E.V., Savel`eva N.Y., Kopylova L.N., Aleksandrovich E.L.